GHRS vs. OLMA, STOK, CALT, ZYME, PHAR, LYEL, ORIC, CSTL, PHAT, and SLN
Should you be buying GH Research stock or one of its competitors? The main competitors of GH Research include Olema Pharmaceuticals (OLMA), Stoke Therapeutics (STOK), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Pharming Group (PHAR), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), Castle Biosciences (CSTL), Phathom Pharmaceuticals (PHAT), and Silence Therapeutics (SLN). These companies are all part of the "medical" sector.
Olema Pharmaceuticals (NASDAQ:OLMA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
Olema Pharmaceuticals presently has a consensus price target of $21.43, suggesting a potential upside of 129.92%. GH Research has a consensus price target of $36.67, suggesting a potential upside of 186.23%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe GH Research is more favorable than Olema Pharmaceuticals.
In the previous week, Olema Pharmaceuticals had 2 more articles in the media than GH Research. MarketBeat recorded 18 mentions for Olema Pharmaceuticals and 16 mentions for GH Research. Olema Pharmaceuticals' average media sentiment score of 0.80 beat GH Research's score of 0.58 indicating that GH Research is being referred to more favorably in the news media.
Olema Pharmaceuticals received 4 more outperform votes than GH Research when rated by MarketBeat users. However, 67.86% of users gave GH Research an outperform vote while only 60.53% of users gave Olema Pharmaceuticals an outperform vote.
Olema Pharmaceuticals has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 23.5% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
GH Research is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Olema Pharmaceuticals' return on equity of -14.56% beat GH Research's return on equity.
Summary
GH Research beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get GH Research News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GH Research Competitors List
Related Companies and Tools
